Search results for "Organization"

showing 10 items of 4550 documents

COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the …

2021

High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients’ needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: ‘how can we deal with COVID-19 infection in cancer patients?’ In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health car…

Cancer Research2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)FAVO Federazione delle Associazioni di Volontariato in OncologiaReviewWHO World Health OrganizationCIPOMO Italian College of Primary Hospital Medical OncologistsSICO Società Italiana di Chirurgia OncologicaMedicalNeoplasmsHealth carePandemicMedicinecancerCentral Venous CathetersHumansFNOPI Federazione Nazionale Ordini Professioni InfermieristicheSocieties MedicalAIRO Associazione Italiana Radioterapia e Oncologia clinicaOncologistsClinical Trials as Topictreatmentbusiness.industryHigh mortalityAIOM Associazione Italiana di Oncologia medicaCancerNeoplasms therapyAIOM; cancer; COVID-19; treatment; vaccination; Central Venous Catheters; Clinical Trials as Topic; Humans; Influenza Vaccines; Oncologists; Practice Guidelines as Topic; COVID-19; COVID-19 Vaccines; Neoplasms; Societies MedicalCOVID-19medicine.diseasevaccinationCOMU College of University Medical OncologistsOncologyInfluenza VaccinesFamily medicineFOCE ConFederazione degli Oncologi Cardiologi e EmatologiPractice Guidelines as TopicESMO European Society for Medical OncologybusinessSocietiesSIPO Società Italiana di Psico-OncologiaAIOMESMO open
researchProduct

Making progress against cancer in Europe in 2008.

2008

Europe is facing a cancer epidemic, with rapidly increasing incidence rates. Population growth and ageing will further increase the annual number of new patients with cancer. Cancer is a huge and growing contributor to the burden of disease and premature death within the European Union (EU). One in four of all deaths in the EU is attributable to cancer, and in the age range 45-64 years, the figure is almost one in two deaths. The 27 EU Member States differ greatly in cancer incidence, mortality and survival. Yet at least one-third of the cancer burden is preventable and a further third can be detected early and treated effectively, even on the basis of existing knowledge. "Cancer", however,…

Cancer ResearchEconomic growthPresidencyService delivery frameworkWorld Health OrganizationAge DistributionCancer controlEnvironmental protectionNeoplasmsmedia_common.cataloged_instanceMedicinePopulation growthHumansMass ScreeningEuropean UnionRegistriesEuropean unionMortalityPopulation GrowthHealth policymedia_commonbusiness.industryCancermedicine.diseaseIntegrated careEuropePrimary PreventionOncologybusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation

2013

International audience; umour necrosis factor-α (TNF) is a cytokine endowed with multiple functions, depending on the cellular and environmental context. TNF receptor engagement induces the formation of a multimolecular complex including the TNFR-associated factor TRAF2, the receptor-interaction protein kinase RIP1 and the cellular inhibitor of apoptosis cIAP1, the latter being essential for NF-κB activation. Here, we show that cIAP1 also regulates TNF-induced actin cytoskeleton reorganization through a cdc42-dependent, NF-κB-independent pathway. Deletion of cIAP1 prevents TNF-induced filopodia and cdc42 activation. The expression of cIAP1 or its E3-ubiquitin ligase-defective mutant restore…

Cancer ResearchLung NeoplasmsBlotting WesternFluorescent Antibody Techniquemacromolecular substancesCDC42BiologyTransfectionInhibitor of Apoptosis ProteinsMice03 medical and health sciences0302 clinical medicineCell AdhesionGeneticsAnimalsHumansImmunoprecipitationNeoplasm InvasivenessPseudopodia[SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronicscdc42 GTP-Binding ProteinMolecular Biology030304 developmental biology0303 health sciencesTumor Necrosis Factor-alphaActin cytoskeleton reorganizationCell PolarityActin remodelingSurface Plasmon ResonanceActin cytoskeletonCell biologyActin CytoskeletonDisease Models AnimalHEK293 CellsCdc42 GTP-Binding Protein030220 oncology & carcinogenesisNIH 3T3 CellsHeterografts[ SPI.NANO ] Engineering Sciences [physics]/Micro and nanotechnologies/MicroelectronicsPseudopodiaSignal transductionFilopodiaSignal TransductionOncogene
researchProduct

Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of…

2021

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic cutaneous lymphoma. Differential diagnosis with lupus erythematosus panniculitis (LEP) can be challenging and overlapping cases have been described. In this study, we investigate whether gene expression profiling may or not identify markers that can be used to improve our understanding of the disease and to make a precise differential diagnosis. SPTCL, LEP, and overlapping cases were analyzed using a customized NanoString platform including 208 genes related to T-cell differentiation, stromal signatures, oncogenes, and tumor suppressor genes. Gene expression unsupervised analysis of the samples differentiated SPTCL f…

Cancer ResearchPathologymedicine.medical_specialtyPanniculitiseducationBiologyLymphoma T-CellCutaneous lymphomaDiagnosis Differential03 medical and health sciences0302 clinical medicineSubcutaneous Panniculitis-Like T-Cell LymphomaPanniculitis Lupus ErythematosusmedicineHumansT-cell lymphomahealth care economics and organizationsLupus erythematosusHematologymedicine.diseaseImmunohistochemistryLymphomaGene expression profilingOncology030220 oncology & carcinogenesisDifferential diagnosishormones hormone substitutes and hormone antagonistsLupus erythematosus panniculitis030215 immunologyLeukemia & Lymphoma
researchProduct

Registration of childhood cancer: Moving towards pan-European coverage?

2015

Cancer is relatively rare in childhood, but it contributes considerably to childhood mortality, years of life lost per person and late effects in survivors. Large populations need to be covered to set up meaningful studies of these rare conditions. Cancer registries ensure cancer surveillance, thus providing the basis for research as well as policy decisions. In this paper we examine coverage of childhood population by cancer registries in Europe and encourage national cancer registration. Over 200 cancer registries in various stages of development were identified as collecting data on childhood cancer patients in Europe. They cover 52% of the childhood population in the World Health Organi…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentChildhood cancerPopulation610 Medicine & healthWorld Health OrganizationNeoplasmsEnvironmental healthHumansMedicinemedia_common.cataloged_instance1306 Cancer ResearchEuropean UnionRegistriesAge of OnsetEuropean unionChildeducationmedia_commoneducation.field_of_studyData collectionbusiness.industryIncidence (epidemiology)Infant NewbornInfantCancer10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseaseEuropeYears of potential life lostOncologyChild PreschoolData qualityPractice Guidelines as Topic2730 OncologybusinessEuropean Journal of Cancer
researchProduct

Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymph…

2003

Hyperuricemia (HU) and tumour lysis syndrome (TLS) are complications of acute leukaemia and non-Hodgkin lymphoma (NHL) leading to increased morbidity and mortality. The objective of this study was to define incidence and calculate health care cost associated with HU and TLS. 788 acute leukaemia and NHL patients from Belgium, The Netherlands, Spain and UK were screened retrospectively for HU and TLS. Resource use related to HU and TLS was recorded and costs were calculated applying local unit costs. Results showed that HU occurred in 18.9% of patients, and 27.8% of them fulfilled TLS criteria. The cost of HU without TLS was 672 euros (SE 181), the cost of TLS 7,342 euros (SE 1,412). TLS requ…

Cancer Researchmedicine.medical_specialtyPediatricsmedicine.medical_treatmentHyperuricemiaRenal DialysisRisk FactorsIntensive caremedicineRasburicaseHumansHyperuricemiaChildhealth care economics and organizationsDialysisNetherlandsLeukemiabusiness.industryIncidenceLymphoma Non-HodgkinIncidence (epidemiology)Age FactorsDisease ManagementHealth Care CostsHematologyMiddle Agedmedicine.diseaseUnited KingdomLymphomaSurgeryNon-Hodgkin's lymphomaTumor lysis syndromeOncologySpainAcute DiseaseHealth ResourcesTumor Lysis Syndromebusinessmedicine.drugLeukemia & Lymphoma
researchProduct

Building an advocacy model to improve the dementia-capability of health plans in California

2021

Background Given the high and growing prevalence of Alzheimer's disease and related dementias, and the intensity of this population's care needs, it is imperative that healthcare systems increase their capacity to effectively serve people living with dementia (PLwD). The Dementia Cal MediConnect (Dementia CMC) project proposes an advocacy model that may foster dementia-capable systems change. Methods The Dementia CMC project was a 5-year partnership (2013-2018) between local Alzheimer's organizations and 10 managed care health plans (HPs) in California's duals demonstration. It used an advocacy model with the following steps: (1) Identify dementia-capable best practices to set as systems ch…

Capacity BuildingSystems AnalysisReferralBest practicePopulationPatient AdvocacyPublic-Private Sector PartnershipsCaliforniaNursingAlzheimer DiseaseHumansMedicineDementiaBusiness caseeducationeducation.field_of_studyGovernmentbusiness.industrymedicine.diseaseOrganizational InnovationGeneral partnershipVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Geriatri: 778Managed careDementiasense organsGeriatrics and GerontologybusinessDelivery of Health Care
researchProduct

OFN Capital Budgeting Under Uncertainty and Risk

2017

The aim of this chapter is to propose a new approach to incorporating uncertainty into capital budgeting. The chapter presents methods that can be used by an investor when the decision maker wants to be able to make an investment decision where there are alternative investment projects. This kind of problem is undertaken under the conditions of uncertainty and risk using Ordered Fuzzy Numbers (OFN). The starting point is the concept of Ordered Fuzzy Numbers. The chapter illustrates the implementation of the proposed approach with an example where two alternative investment projects are analyzed. The authors present the capital budgeting problem using a numerical example. The described metho…

Capital budgetingOperations researchProject selectionEconomicsFuzzy numberAlternative investmentProfitability indexDiscount pointsInvestment (macroeconomics)Fuzzy logicIndustrial organization
researchProduct

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity

2007

Background and aim: The clinical use of doxorubicin (DOX) and other anthracyclines is limited by a dosage-dependent cardiotoxicity, which can lead to cardiomyopathy. The role of the individual genetic makeup in this disorder is poorly understood. Alterations in genes encoding cardiac cytoskeleton or sarcolemma proteins may increase the susceptibility to doxorubicin-related cardiotoxicity. Methods: Female dystrophin-deficient mice (MDX) and age-matched wild-type mice underwent chronic treatment with doxorubicin. Cardiac function and tissue damage were assessed by echocardiography and histopathology, respectively. Gene expression changes were investigated using microarrays. Results: DOX treat…

Cardiac function curveProgrammed cell deathPathologymedicine.medical_specialtyHeart DiseasesCytoskeleton organizationCardiomyopathyGene Expression030204 cardiovascular system & hematologyDystrophinMice03 medical and health sciences0302 clinical medicineRisk FactorsmedicineAnimalsDoxorubicinUltrasonography030304 developmental biology0303 health sciencesCardiotoxicityAntibiotics AntineoplasticSarcolemmabiologybusiness.industryGenetic VariationMicroarray Analysismedicine.disease3. Good healthDoxorubicinDisease Progressionbiology.proteinCancer researchFemaleDisease SusceptibilityCardiology and Cardiovascular MedicineDystrophinbusinessmedicine.drugEuropean Journal of Heart Failure
researchProduct

Dose Responsive Effects of Subcutaneous Pentosan Polysulfate Injection in Mucopolysaccharidosis Type VI Rats and Comparison to Oral Treatment

2014

Background We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (s.c.) injection. The bioavailability of injected PPS is greater than oral, suggesting better delivery to difficult tissues such as bone and cartilage. Injected PPS also effectively treats osteoarthritis in animals, and has shown success in osteoarthritis patients. Methodology/principal findings One-month-old MPS VI rats were given once weekly s.c. injections of PPS (1, 2 and 4 mg/kg, human equivalent dose (HED)), or daily oral PPS (4 mg/kg HED) for 6 months. Serum inflammato…

Cartilage ArticularMaleMucopolysaccharidosisMucopolysaccharidosis type VIlcsh:MedicineAdministration OralOsteoarthritisOral administrationMedicine and Health SciencesFemurGrowth Platelcsh:Sciencehealth care economics and organizationsGlycosaminoglycansPentosan Sulfuric PolyesterMucopolysaccharidosis VIMultidisciplinaryMucopolysaccharidosis VIPentosan polysulfateBiomechanical Phenomena3. Good healthFemaleAnatomyResearch Articlemedicine.drugmedicine.medical_specialtyInflammatory DiseasesInjections SubcutaneousMovementeducationUrologyBiological AvailabilityResearch and Analysis MethodsDrug Administration ScheduleAutosomal Recessive DiseasesGeneticsmedicineAnimalsAnimal Models of DiseaseBoneAdverse effectMolecular BiologyClinical GeneticsDose-Response Relationship Drugbusiness.industrylcsh:RTherapeutic effectBiology and Life SciencesMucopolysaccharidosesmedicine.diseaseSpineRatsSurgeryAnimal Studieslcsh:QVeterinary ScienceTomography X-Ray ComputedbusinessPLoS ONE
researchProduct